Description
Release form
Eye drops.
Packaging
In a polymer dropper bottle, 2.5 ml solution. In the package 1 bottle.
Pharmacological action
Glauprost is an anti-glaucoma drug. Is prostaglandin F2 analogue and a selective FP receptor agonist. It reduces intraocular pressure by increasing the outflow of aqueous humor, mainly along the uveoscleral pathway, as well as through the trabecular network. It does not significantly affect the production of aqueous humor and does not affect the blood-brain barrier. The decrease in intraocular pressure begins 3-4 hours after the administration of the drug, the maximum effect is observed after 8-12 hours, the effect lasts for at least 24 hours.
Pharmacokinetics
It penetrates well through the cornea, with hydrolysis to a biologically active form. The time to reach maximum concentration (TS max) in aqueous humor is 2 hours after topical application.
In the tissues of the eye, latanoprost acid is practically not metabolized. Metabolism occurs mainly in the liver. The half-life (T 1/2) is 17 minutes. The main metabolites – 1, 2-dinor and 1,2,3,4-tetranoromethabodites do not or have weak biological activity.
Excreted by the kidneys.
Indications
Open angle glaucoma.
Increased intraocular pressure.
Contraindications
Individual hypersensitivity to latanoprost, benzalkonium chloride or other components of the drug.
Age to 18 years.
Caution:
Afakia.
Pseudo-aphakia.
Rupture of the posterior lens capsule.
In patients with known risk factors for macular edema (in the treatment of latanoprost, cases of the development of macular edema, including cystoid edema, have been described).
Inflammatory, neovascular or congenital glaucoma (due to lack of sufficient experience with the drug).
Use during pregnancy and lactation
Use of Glauprost during pregnancy is possible only under the supervision of a doctor and only if the expected benefit to the mother outweighs the risk of possible side effects in the fetus.
Latanoprost and its metabolites may be excreted in breast milk. If necessary, the appointment of Glauprost during lactation, breastfeeding should be discontinued.
Composition of
In 1 ml of a solution of eye drops contains:
Active ingredient
Latanoprost 0.05 mg.
Excipients
Disodium hydrogen phosphate dodecahydrate 17.00 mg, sodium dihydrogen phosphate dihydrate 7.00 mg, sodium chloride 3.00 mg, benzalkonium chloride 0.20 mg, purified water to 1 ml.
Dosage and administration
In the conjunctival sac of the affected eye, instill 1 drop 1 time per day, in the evening.
When skipping a dose, the next one is administered as usual (i.e. do not double the dose).
Side effects
On the part of the organ of vision
Eye irritation (burning sensation, sensation of sand in the eyes, itching, tingling and sensation of a foreign body), blepharitis, conjunctival hyperemia, pain in the eyes, increased iris pigmentation, transient epithelium from edema, transient epithelium, erotica swelling and erosion of the cornea, conjunctivitis lengthening, thickening, increase in the number and increase in pigmentation of eyelashes and vellus hair, a change in the direction of eyelash growth, sometimes causing eye irritation, iritis / uveitis, keratitis, macular edema (including cystoid), blurred vision.
Dermatological reactions
Rash, darkening of the skin of the eyelids and local skin reactions of the eyelids.
From the nervous system
Dizziness, headache.
From the respiratory system
Bronchial asthma (including acute attacks or exacerbation of the disease in patients with a history of bronchial asthma), shortness of breath.
From the musculoskeletal system
Muscle pain, joint pain.
Other
Nonspecific chest pain.
Drug Interaction
Pharmaceutically incompatible with thiomersal-precipitated eye drops.
When prescribing combination therapy, eye drops of various drugs should be administered at intervals of at least 5 minutes.
Simultaneous instillation of two prostaglandin analogues may cause a paradoxical increase in intraocular pressure.
overdose
Symptoms: irritation of the mucous membrane of the eye, hyperemia of the conjunctiva or episcleras.
Treatment: symptomatic.
Storage conditions
Store in a dark place at a temperature of 2 ° to 8 ° C. After opening the bottle, the drug should be stored at a temperature not exceeding 25 ° C.
Expiration
3 years. After opening the vial, the drug should be used within 4 weeks.
Active ingredient
Latanoprost
dosage form
dosage form
eye drops
K.O.Romfarm Company S.R.L., Romania
